Nasdaq confirms Evaxion is fully compliant, withdraws delisting determination
February 14, 2025 08:00 ET
|
Evaxion Biotech
Evaxion will remain listed on Nasdaq after successfully evidencing compliance with the Nasdaq minimum stockholders’ equity requirement Evaxion has restored its equity above the minimum requirement...
Evaxion announces closing of $10.8 million public offering
January 31, 2025 16:05 ET
|
Evaxion Biotech
COPENHAGEN, Denmark, January 31, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced the...
Evaxion announces pricing of $10.8 million public offering
January 30, 2025 08:00 ET
|
Evaxion Biotech
COPENHAGEN, Denmark, January 30, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced the...
Evaxion reports convincing one-year data from phase 2 trial on AI-designed personalized cancer vaccine EVX-01
September 16, 2024 07:00 ET
|
Evaxion Biotech
11 out of 16 patients had objective clinical responses, equaling a 69% Overall Response Rate15 out of the 16 patients had a reduction of their tumors (target lesions)79% of EVX-01’s vaccine targets...
Evaxion to Announce Business Update and Second Quarter 2024 Financial Results on August 14
August 12, 2024 07:27 ET
|
Evaxion Biotech
COPENHAGEN, Denmark, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™...
Evaxion Reinforces Milestone Timeline and Provides Shareholder Update
July 03, 2024 08:05 ET
|
Evaxion Biotech
COPENHAGEN, Denmark, July 03, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™...
AGC Biologics and Evax Partner to Advance Promising Equine Allergy Vaccine Candidate
September 07, 2022 17:00 ET
|
AGC Biologics
Seattle, Sept. 07, 2022 (GLOBE NEWSWIRE) -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a new partnership with Evax,...